Here’s Why Traders Are Buzzing Around Lions Gate, Stellar Biotechnologies, and Three Other Stocks

Page 2 of 2

Ampio Pharmaceuticals’ Stock Punished after Failed Trial

Ampio Pharmaceuticals Inc (NYSEMKT:AMPE)’s stock has lost around 56% so far after the company announced that phase 3 trial of osteoarthritis pain treatment missed its primary endpoint. The primary endpoint was the change in WOMAC A pain at week 12 as compared to saline, but the overall response recorded only 20% improvement in pain. Fred Knoll’s Knoll Capital Management is one of just fou hedge funds followed by us that reported stakes in Ampio Pharmaceuticals Inc (NYSEMKT:AMPE) as of the end of March this year.

Follow Ampio Pharmaceuticals Inc. (NYSE:AMPE)

Lions Gate to Acquire Starz

Lions Gate Entertainment Corp. (USA) (NYSE:LGF) and Starz (NASDAQ:STRZA) are making headlines today after the announcement that  Lions Gate will acquire Starz in a cash-and-stock deal, valued at $4.4 billion including debt. The deal unifies a major movie maker with the second-biggest cable network in the US. Under the terms of the deal, Starz’s Class A shareholders will receive $18 in cash per share and two-thirds of a share of Lions Gate’s non-voting stock. With ownership of 20 million shares, billionaire Warren Buffett’s Berkshire Hathaway is a one of 34 funds tracked by us that own class A shares of Starz (NASDAQ:STRZA) as of the end of the first quarter. On the other hand, 32 funds reported stakes in Lions Gate Entertainment Corp. (USA) (NYSE:LGF) in the same period. Among them, Mark Rachesky’s MHR Fund Management has more than 30.2 million shares of the company.

Follow Lions Gate Entertainment Corp (NYSE:LGF.B)

Follow Starz Acquisition Llc (NASDAQ:STRZA)

Disclosure: none

Page 2 of 2